GI CANCERS

Latest News

PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer
PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer

March 27th 2024

During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.

FDA Fast Tracks PT886 in CLDN18.2+ Pancreatic Cancer
FDA Fast Tracks PT886 in CLDN18.2+ Pancreatic Cancer

March 21st 2024

First-Line Nivolumab/Ipilimumab Improves Survival in Hepatocellular Cancer
First-Line Nivolumab/Ipilimumab Improves Survival in Hepatocellular Cancer

March 20th 2024

New Clues to Pancreatic Cancer Subtypes' Unique Vulnerabilities
New Clues to Pancreatic Cancer Subtypes' Unique Vulnerabilities

March 9th 2024

Cambritaxestat Wins FDA Orphan Drug Designation in Pancreatic Cancer
Cambritaxestat Wins FDA Orphan Drug Designation in Pancreatic Cancer

March 7th 2024

More News